Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

High-frequency ultrasound with elastography improves skin cancer diagnosis

High-frequency ultrasound with elastography can help differentiate between cancerous and benign skin conditions, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2009

BSGI proves to be an effective adjunct imaging modality for detecting DCIS

Breast-Specific Gamma Imaging (BSGI) has been proven to be a highly sensitive imaging technique for the detection of ductal carcinoma in situ (DCIS), a difficult to diagnose breast cancer. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers.

30 Nov 2009

Elastography decreases breast biopsies and maps tumors more precisely

Elastography is an effective, convenient technique that, when added to breast ultrasound, helps distinguish cancerous breast lesions from benign results, according to an ongoing study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2009

Wnt signaling pathway plays a role in diabetic retinopathy

A group led by Dr. Jian-xing Ma at The University of Oklahoma Health Sciences Center, Oklahoma City, OK has demonstrated that the Wnt signaling pathway plays a role in diabetic retinopathy.

26 Nov 2009

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups

25 Nov 2009

People with severe EBS at increased risk of skin cancer, say scientists

UK scientists have discovered the link between people with the skin blistering disease Epidermolysis Bullosa Simplex-Dowling-Meara, (EBS -DM) - and tumour growth, according to research published in Journal of Investigative Dermatology today (Monday).

25 Nov 2009

New finding reveals Barrett's esophagus in asymptomatic women undergoing endoscopic screening

In the November issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE), a study out of Stanford University found that Barrett's esophagus was detected in six percent of asymptomatic women undergoing endoscopic screening.

24 Nov 2009

Physical exercise - one of the most effective methods of preventing disease

Physical exercise is one of the most effective methods of preventing disease. The current issue of Deutsches -rzteblatt International is devoted to this important topic.

24 Nov 2009

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).

23 Nov 2009

Cancer promoting gene identified

Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Scientists hope the finding could lead to an effective therapy to target and inhibit the expression of this gene resulting in inhibition of cancer growth.

21 Nov 2009

Antigenics to withdraw its MAA for Oncophage following CHMP’s negative opinion

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) as a treatment in earlier-stage, localized renal cell carcinoma (kidney cancer).

20 Nov 2009

2nd EMUC Meeting to discuss urological cancer

Experts agree that the urological cancer patient will benefit greatly if the delivered treatment is the result of a combined effort. Collaboration of experts from various fields is, therefore, necessary to take cancer-related research and medical practice to the next level.

20 Nov 2009

Report on unexplained liver haemorrhage after metastasis radiofrequency ablation published

Colorectal carcinoma is one of the most common cancers in the world. Approximately one in four of these patients have metastases at diagnosis, liver being the most common site involved. Although historically it was considered that liver metastases meant a very poor prognosis, today, due to improved systemic therapy, many patients will be candidates for local hepatic treatments such as surgery or less aggressive radiofrequency ablation.

19 Nov 2009

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

Opiate-based painkillers can increase tumor-cell proliferation, says new study

Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.

19 Nov 2009

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.

19 Nov 2009

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

BSD Medical Corporation (www.bsdmedical.com) today provided an update on the U.S. Food and Drug Administration’s (FDA) review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.

18 Nov 2009

Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC

Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee's Pharmaceutical Holdings, the execution of a collaboration and license agreement for Jennerex's lead product candidate, JX-594, in certain Asian territories.

18 Nov 2009

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.

18 Nov 2009

Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers

Oncolytics Biotech Inc. today announced updated results from a Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers in a poster presentation at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts.

17 Nov 2009